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The recognition of the primacy of enthesitis in animal models of spondyloarthritis (SpA) and 
the prevalence of clinically occult enthesopathy in psoriatic subjects and of persistent joint 
pain in psoriatic arthritis subjects that have osten ibly good reduction of joint swelling under 
biological therapy has highlighted the potential impact of polyenthesitis in psoriatic disease. 
In daily practice the formal demonstration of enthesitis is challenging due to: the relatively 
avascular nature of enthesis often leading to the abs nce of overt clinical inflammatory signs; 
the frequent lack of inflammatory markers elevation; fi ally, the limitations of current 
imaging techniques to provide supportive evidence for inflammation in these areas. 
Consequently, enthesitis may present as widespread ain indistinguishable from fibromyalgia 
or may emerge as the dominant feature after successful biological therapy for suppressing 
synovitis. The unmet needs in the differentiation between fibromyalgia and enthesitis in 
psoriatic disease subjects are highlighted and critically evaluated in this article. 
 
KEY WORDS: Spondylarthropathies; Fibromyalgia; Chronic pain sydromes; Soft tissue 
rheumatism; Inflammation; Diagnostic imaging; MRI; adionuclide imaging; 
Ultrasonography; Biological therapies 
KEY MESSAGES 
1) Entheses are avascular, well-innervated structures without gold standard clinical, serum 
biomarkers, imaging or histological outcomes. 
2) There is considerable difficulty in distinguishing between pain from enthesitis or from 
fibromyalgia. 
3) Differentiating fibromyalgia from enthesitis symptoms is crucial in patients failing to 
respond to treatment. 
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Introduction and relevant patho-biology 
Enthesitis is defined as inflammation occurring in the interface where tendons, ligaments, and 
capsules attach to the bones. Pain, tenderness and stiff ess (with or without apparent 
swelling) are its main clinical manifestations. Enthesitis plays an important role in the 
understanding of psoriatic arthritis (PsA) and other forms of spondyloarthritis (SpA) [1, 2]. 
Several animal models demonstrate that PsA-like disase starts at the enthesis before 
spreading to adjacent synovium and bone [3-5]. In patients with psoriasis, imaging studies 
show a high burden of pauci-symptomatic enthesopathy[6]. Psoriatic nail disease, a clinical 
predictor of future PsA [7], is also strongly linked to local [8] and remote [9] enthesopathy. 
From a physiological view point, entheses are completely avascular at attachment sites and 
have a low density of blood vessels in the adjacent ligaments and tendons. Furthermore, 
entheseal regions are well innervated. 
In comparison, synovial tissues are highly vascular and undergo extensive hyperplasia with 
inflammatory immune cell infiltration with related articular cavity effusions during 
inflammatory episodes. Because of the different anaomical structure, enthesitis may lead to 
increased vascularisation (sometimes detectable only through dynamic imaging) (Fig. 1B) 
and mild swelling of the surrounding soft tissues. In most cases, however, enthesitis occurs 
without visible signs of clinical inflammation. 
SpA-related enthesitis occurs most typically in association with joint swelling when the 
integral synovio-entheseal complex is involved. In this case it is not clinically possible to 
distinguish enthesitis from synovitis. Many entheses are placed deep inside the human body 
and consequently they are not clinically accessible, which undermines the diagnostic process 
unless considering the use of sensitive and advanced imaging techniques. Histological tissue 
sampling of entheses as a diagnostic gold standard is lso unfeasible. In addition, age- and/or 
overweight-related changes do occur at entheseal sit s (Figure 1, panels C, D) as 
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degenerative features [10, 11], which may limit the us fulness of imaging, including 
ultrasound (US) and magnetic resonance (MRI). Finally, nother result of the peculiar 
anatomical structure of entheses is the lack of correlation with acute phase reactants. 
Following on from these anatomical considerations the specific difficulties that multi-
enthesitis poses in differentiating this condition from fibromyalgia are discussed. 
 
Fibromyalgia 
Fibromyalgia syndrome (FMS) is a complex chronic widespread pain (CWP) disorder of 
unknown origin, classified as primary or concomitant to other conditions (e. g. several 
rheumatic diseases, thyroid disorders, etc.) and has been well reviewed elsewhere[12-14]. 
The presence of FMS in ankylosing spondylitis (AS) and axial SpA subjects can distort 
disease activity measures towards more severe activity scores [15-17]. In psoriasis, the 
prevalence of FMS has been reported ranging between 5.4-8.3% [18, 19], which is higher 
than that found in the general population [20]. On the other hand, one abstract suggested that 
up to 93% of FMS subjects may show US signs of enthesopathy[21]. 
FMS is associated with abnormalities in pain processing in the central nervous system [12], 
although no specific abnormalities have been found in peripheral nociceptive systems in the 
skin and soft tissues of these subjects. In contrast, studies using functional brain imaging 
techniques [22] suggested abnormal pain processing mechanisms in FMS. 
Despite these data supporting the unifying concept of central sensitivity syndrome [14], FMS 
is mostly a diagnosis of exclusion and there is no gold standard confirmatory test or 
biomarker [23]. In addition to widespread pain, stiffness, fatigue and non-restorative sleep, 
patients often complain of other symptoms including paraesthesiae, swelling-like feeling in 
the extremities of the limbs, cognitive difficulties, headaches, irritable bowel syndrome, 
interstitial cystitis, and many other autonomic dysfunctions. Such features might be 
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confounders [24], since PsA shares with other SpA the axial involvement (often associated 
with fatigue and poor sleeping quality) and/or may overlap with inflammatory bowel diseases 
(which usually lead to intestinal discomfort). The n ed to differentiate between functional or 
organic origin of symptoms requires wider investigations and the need for a multi-
disciplinary approach. 
The presence on clinical examination of tender points, elicited by palpation at specific sites, 
was part of the 1990 classification criteria of FMS [25]. Since tender points count is still 
widely used, the substantial anatomical overlap betwe n these and many entheseal sites [26] 
may mislead the clinician in one way or the other. 
More recently, a revised set of FMS diagnostic criteria has been proposed, excluding tender 
point examination and including somatic symptoms [27]. A modification of that revision [28] 
has been validated [29]. Despite this, CWP remains the clinical mainstay of FMS and painful 
reaction to pressure at discrete body areas often is considered to be suspicious of either FMS 
or multiple enthesitis. 
 
Enthesitis manifesting as fibromyalgia, a PsA subgroup with multiple enthesitis 
Historically, the Moll and Wright criteria for PsA [30] did not encompass any purely 
enthesitic subgroup. Nonetheless, in their seminal textbook on SpA from 1976, Wright and 
Moll [31] noted that some patients had bone pain, which we now suspect might have been a 
peri-entheseal osteitis. The relevance of such a clinica  manifestation has been increasingly 
appreciated following imaging observations and theoretical papers in the late 1990s [1, 32, 
33]. Following on these, the CASPAR classification criteria for PsA [34] have fully 
recognised enthesitis as a typical clinical feature of this disease by including it as one of the 
three entry manifestations. Lastly, phase III clinial trials in PsA carried out during the last 
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five years show a higher frequency of assessing entheseal involvement than some earlier 
studies [35-38]. 
It has been postulated that there is a PsA subgroup suffering mostly from enthesitis, without 
associated synovitic manifestations. Obvious examples include costochondritis with related 
thoracic pain; pain over the spine due to interspinal l g ment enthesitis; pain localized in one 
or few entheseal sites; and, presumably, a syndrome characterised by CWP. Due to a lack of 
description in medical literature, it is not currently known if a presentation pattern 
characterized by symmetrical distribution in the sit s of insertional pain might provide a 
clinical clue to genuine primary FMS, while a rather scattered, multi-site distribution of 
symptoms apparently linked with mechanical stresses (w ight, manual activities, and posture) 
could represent multi-enthesitis. 
In the light of the similarities with FMS symptoms and the overlap between many entheseal 
sites and the classic FMS tender points, such patients can be misdiagnosed as having FMS. 
To make things more complicated, there is a lack of to ls that can reliably demonstrate 
enthesitis in this subgroup. Also, patients with a somatosensory predisposition to FMS [22] 
might develop the latter condition in addition to their enthesitis. Conversely, psoriatic patients 
with primary FMS might perceive as painful mild entheseal inflammation which, otherwise, 
would be clinically silent. Both situations might represent a co-occurrence of two common 
conditions or a true PsA-FMS overlap disease. Another possible scenario is that psoriatic 
patients with synovitis and/or spondylitis may eventually develop secondary CWP. Even in 
this context, understanding whether the predominant underlying pain is a symptom of multi-
enthesitis, FMS or a co-occurrence of both may prove t  be difficult. A similar scenario is 
well recognised in patients with other inflammatory a thropathies such as rheumatoid arthritis 
or osteoarthritis, where FMS or CWP may develop as a concomitant or superimposed 
syndrome [39, 40]. 
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Another possible confounding situation is represented by patients with CWP and a genetic 
predisposition to psoriasis or to SpA. Although these subjects might well have multi-
enthesitis, they are likely to be diagnosed as having FMS alone. This reasoning implies that 
in the case of CWP it is worth looking carefully foractors predisposing to enthesitis, such as 
familial history of psoriasis, SpA or associated diseases. The therapeutic implications of PsA 
overlapping with FMS may be relevant in many respects, because data suggest decreased 
chances of achieving remission in this sub-group[41]. A simplified strategy for dealing with 
these entangled issues is summarised in Figure 2. 
 
Primary enthesitis diagnosed as FMS 
Tumor Necrosis Factor α inhibitors (TNFi) treatment has been particularly successful in the 
context of AS and PsA. More recent developments targe  the interleukin-23 and interleukin-
17 axis. Since the first clinical trials to test biologics efficacy, the indication to start such 
therapies in PsA has been poly-synovitis. As mentioned above, however, there is increasing 
interest in evaluating the effects of biologic therapies on enthesitis [35, 36, 38]. International 
recommendations for the treatment of PsA [42, 43] suggest biologic therapy for enthesitis, 
when it is severe enough and not controlled by Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) or local steroid injections. There are two noteworthy scenarios, when considering 
the use of biologics in the context of suspected multi-enthesitis/CWP. 
PsA with joint swelling and associated insertional pain 
Patients eligible for biologic therapy usually experience significant benefits on signs and 
symptoms of synovitis when treated with biologics. Improvements in enthesis involving 
superficial areas (e. g. Achilles’ tendon) have been widely observed in clinical practice 
following the use of biologics. As a result, psoriatic patients suffering from CWP on top of 
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synovitis who would show a good response after a trial of therapy including NSAIDs, 
corticosteroids or even biological agents might be assumed to have enthesitis rather than 
FMS. 
Poly-synovitis remitting after the therapy, leaving diffuse insertional pain 
When patients with active poly-arthritic PsA are trated with biological drugs, the joint count 
usually shows dramatic improvements, along with a fall in C-reactive protein levels. In some 
cases, however, regardless of a successful action in suppressing joint swelling and 
normalising inflammatory markers, on-going pain seemingly related to the entheses may 
persist, suggesting a possible concomitant/supervening FMS. 
The assessment of such patients largely relies on clinical parameters. Thus far, scarce 
evidence supports any strategy which would rely onl  imaging. Interestingly, one small 
prospective study [44] showed that 27.3% of subjects wi h enthesitic SpA had radionuclide 
scanning and MRI evidence of entheseal inflammation s milar to that in patients with definite 
AS or PsA. Although large case-control and prospectiv  studies are lacking, it is possible to 
postulate that instead of scanning only discrete insrtional areas, the whole-body MRI 
(wbMRI) technique could better assist in uncovering genuine entheseal inflammation [45] or 
even detect clinically silent enthesitis [46]. 
Further, the study of Godfrin [44] and co-workers suggests that a favourable response to non-
steroidal anti-inflammatory drugs (NSAIDs) was indicat ve of SpA in subjects presenting 
insertional pain, although the participants had not been previously treated with biologics. In 
general, a significant response to NSAIDs, depot steroid injections or biologics would be 
expected in genuinely inflammatory underlying cause. In clinical practice, however, 
decisions on biologics dose adjusting (or intra-class switching/inter-class swapping) is based 
on a pragmatic and time-consuming approach complicated by the absence of biomarkers 
(figure 2). 
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Primary fibromyalgia, misdiagnosed psoriatic arthritis 
There are few data in literature on this particular scenario. Given the increased utilisation of 
imaging and given that age-related changes may occur at normal entheses, particularly in 
patients with high body mass index (BMI), it is quite possible that patients with FMS may 
show some degree of entheseal change. Indeed, this was hown to be the case in a study 
comparing entheseal ultrasound findings in PsA and FMS patients [47]. Such clinically trivial 
findings could be erroneously ascribed to inflammatory enthesopathy, leading to 
inappropriate conventional disease-modifying anti-rheumatic drugs (DMARDs) or even 
biological treatments. 
 
Imaging techniques: supporting evidence when enthesitis is considered 
As mentioned in the introductory section, the micro-anatomical peculiarities of physiological 
entheses make these structures difficult to assess from the imaging point of view. Several 
techniques are available, or under development, to look for inflammatory lesions in the 
entheses. 
Conventional radiography 
This technique has many advantages: it could be considered virtually ubiquitous; time to 
acquire images is fast and costs are limited. Pitfalls are the implied use of ionizing radiations, 
the need of readers trained in musculo-skeletal radiology and, above all, the limitation of 
capturing mostly late-stage lesions (such as large bony erosions and fluffy periosteal bony 
apposition). 
Ultrasound scanning 
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This technique has several interesting characteristics: US scans can provide real-time, 
dynamic, in vivo imaging of the anatomical sites explored and spot increased vascularity. 
Further, they can detect erosions more sensitively than conventional radiography; finally, 
advanced US machines are becoming more compact and heaper. Interestingly, some 
research[48] suggests that psoriatic subjects and PsA cases show abnormal vascularity at 
entheseal level even if asymptomatic, while healthy controls do not. Unfortunately, although 
in the study by Aydin[48] et al. the increased vascularity was more specific for entheseal 
inflammation, the sensitivity was low (36%). Furthermore, the same study found that the 
range of chronic entheseal changes in healthy subjects overlapped the ranges of psoriatic 
subjects and PsA cases. Such results are in keeping with those from a study[47] concerning 
FMS subjects. Another pitfall of the US technique is the need of long training necessary for 
experienced sonographers and the trend to have such professionals mostly available in 
tertiary centres only. Finally, many entheseal sites are not accessible for US scans or the 
symptomatic involvement could be excessively widesprad to be dealt with in a reasonable 
amount of scanning time. 
Magnetic resonance imaging 
wbMRI methods could overcome the difficulties in theassessment of deeply located 
entheses. Furthermore, such approach allows extensive, multi-purpose scans (assessing 
several entheses as well as joints) in one single setting. Considering the data from 
Poggenborg [46] et al., results suggest a remarkable sensitivity of high magnetic field (3 
Tesla) wbMRI in detecting even asymptomatic entheseal lesions. Abnormalities detected 
with 1.5 tesla MRI units seem to have limited correlation with clinical findings [49]. 
Other MRI techniques like ultra-short echo time (UTE), although not applicable on a whole-
body scale, have shown enhanced ability to demonstrate even subtle alterations of entheseal 
vascularity when compared to conventional MRI and US [50]. Although all the above 
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progresses are promising, wbMRI and UTE methods are till under development and time-
consuming. Furthermore, MRI machines able to deliver that kind of imaging are available 
mostly in academic centres. Finally, before widesprad clinical use, the uncertainties 
concerning entheseal abnormalities found among healthy subjects [46] still need robust 
research and clarification. 
Positron emission tomography  
In rheumatology, positron emission tomography (PET) scans are often used in the assessment 
of systemic vasculitidies. PET offers metabolic images that can be coupled with computed 
tomography (CT) scans and MRI. Interestingly, there is vidence of fluorodeoxyglucose 
uptake at the entheseal sites of psoriatic patients [51]. Despite the small sample dimension of 
this study, enhanced entheseal uptake was found in 33% of psoriatic subjects. In another 
study [52], PET scan were abnormal in SpA patients (encompassing one case of PsA), while 
no uptake was found in healthy subjects or non-rheumatic patients. 
Another development of the PET technique in the field of SpA is a radiotracer specific for 
osteoblastic activity (18 F-NaF PET). Some researchers [53] were able to depict 
osteolytic/inflammatory lesions and sclerotic/ossifying lesions in axial SpA subjects, a 
characteristic that could be promising aid in differentiating between FMS and PsA. 
Despite these interesting results, the PET technique is not widely available, utilises ionizing 




Patients with PsA may be overweight and biomechanical problems may contribute to pain 
around enthesis as well as to FMS pain. For foot or knee mechanical abnormalities, such as 
pes planus or genus valgus, attention to podiatry ma  have a role. These patients also show 
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strong clinical overlaps with generalised nodal oste arthritis and spinal degenerative changes. 
Sleep apnoea, often linked to BMI which is usually e evated in PsA, may contribute to 
increased levels of pain, although its role in the int rplay between CWP and increased body 
mass is still uncertain [54]. 
It could be anticipated that patients with non-inflammatory entheseal discomfort may have 
anxiety and depressive symptoms, which are common in PsA patients as confounding factors 
[55]. Some evidence suggests that psychological factors an impact the measurement of 
disease severity [56], although this issue was not specifically addressed in a PsA population 
characterized by isolated entheseal involvement. 
Finally, in a small study psoriasis has been associated with cognitive dysfunctions [57], 
which might have an effect of pain perception. However, there are no data on this specific 
issue. 
 
Practical approach to the management of patients with psoriatic disease when enthesitis 
or fibromyalgia are suspected 
When dealing with a psoriatic patient or even with a potentially psoriatic patients (i.e., 
familial history of psoriasis) who are complaining of CWP, all of the following possible 
phenotypic patterns should be contemplated in the diagnostic process: i) Multi-enthesitis; ii) 
FMS; iii) A combination of the two conditions; iv) Other joint diseases. 
The presence of long-lasting morning stiffness and  sustained response to a course of 
steroids would certainly be more suggestive of genuine multi-enthesitis. A higher number of 
somatoform symptoms [58] would point more towards FMS (figure 3). 
FMS patients often have pain and tenderness not only in specific points but also in other sites, 
reflecting the reduction in pain threshold, and in addition always have fatigue and non-
restorative sleep. Otherwise, concomitant peripheral and/or axial articular inflammatory 
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involvement would clearly suggest PsA. Similarly, altered inflammatory markers in the 
absence of any other possible explanation may be indicative of SpA. 
Imaging may be helpful in some cases, although verysophisticated imaging such as wbMRI 
is usually not available in daily practice. A study of entheseal PDUS showed that a high 
number of involved sites, a high grey-scale score, a high power-Doppler score in one site, and 
involvement of typical sites (e.g., the Achilles’ tendon) were significantly associated with 
PsA rather than FMS [59], although the sensitivity of these findings was relatively low. 
Furthermore, age- and weight-related degenerative changes should always be considered as 
sources of confounding. 
Even if symptoms, sustained versus lack of response to teroids or NSAIDs, laboratory tests, 
objective findings upon clinical examination, PDUS of the entheses or other imaging may 
help to point towards multi-enthesitic PsA or FMS, it is always possible that the two 
conditions coexist as a co-occurrence or overlap disease. In these cases making a correct 
diagnosis is the first challenge, the second being to dynamically understand which one of the 
two conditions is the leading cause of discomfort. 
Since conventional DMARDs seem to be poorly effective in genuine multi-enthesitis, the 
absence of response to these drugs is not usually helpful. Conversely, given the 
acknowledged efficacy of biologics on enthesitis [36, 42, 60], FMS should be reconsidered if 
there is a lack of response. However, as not all PsA patients with enthesitis improve upon 
anti-TNFα therapy, the final diagnosis should be based on the integration of all the clinical 
and imaging findings. 
All the above suggests that a holistic approach is needed, both in the initial diagnostic phase 
and in the long-term management. Agents such amitriptyline, gabapentin, pregabalin, or 
doluxetine may be used. Although there are no data, it is conceivable that these agents may 
also have an effect on pain related to the enthesopathy. Of note, it is known that abnormal 
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innervation of enthesis in the spine contributed to egenerative disc disease. However, there 
are no data so far on abnormal innervation of enthesis that have previously been inflamed due 
to a bout of SpA. 
Finally, if patients have severe inflammatory symptoms, it may be that a trial of biological 
therapy and an assessment of response may be the only to l available to differentiate between 
FMS and multi-enthesitis. This is reminiscent of the use of steroids in suspected normal acute 
phase response polymyalgia rheumatica, where often a rial of therapy is ultimately used to 
make the diagnosis. 
 
Conclusions and future directions 
There is an increased awareness that psoriatic patients may have CWP. It is difficult to 
differentiate whether these patients have multi-enth si is, FMS or both, as the physical 
examination may be similar and other clinical features need to be taken into consideration. 
Some points seem noteworthy: i) Early stage enthesitic PsA cases may be diagnosed as FMS 
if evaluated prior to development of dactylitis and/or synovitis or of musculoskeletal 
symptoms occur with not apparent psoriasis; ii) Differentiation of the two conditions may be 
suggested by steroid responsiveness. Lack of benefit or short-lived atypical steroid response 
may suggest FMS, especially when associated with mood disorders or somatisation; iii) 
Imaging with PDUS or selected MRI scanning of limited sites of predominant pain, if 
wbMRI is not available, could be utilised.  
Although a comprehensive approach should be helpful, the diagnosis and management may 
be challenging. On a positive note, patients with enth seal disease with normal x-rays, 
absence of joint swelling and normal C-reactive protein are unlikely to develop progressive 
structural damage. 
Page 15 of 25 
 
More recent imaging approaches, such as wbMRI scans and F18-Na PET/CT (figure 4), 
could improve our understanding of the interplay betwe n enthesopathies and FMS. This is 
an area that warrants further research. 
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TABLES AND FIGURES 
 
Figure 1. Clinical case: 48-year-old woman, mild psoriasis 
 
Onset of pain in the elbows and hips, then evolved to widespread musculo-skeletal pain. 
Other symptoms: moderate-severe fatigue, morning stffness, sleep disturbances, anxiety. 
Initial diagnosis of fibromyalgia, paracetamol and duloxetine not effective. Then 
indomethacin: slight improvement. Enthesitis suspected (see B), sulphasalazine trial 
ineffective. Biologic treatment: impressive improvem nt. A: enthesis, normal appearance. B, 
empty arrow: presence of power-Doppler signal in the enthesis. C, D: thin white arrows 
indicate enthesophytes. 
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Anaemia, heart failure, drugs, neoplasms, nutritional factors and endocrinopathies have to be 
taken into account for differential diagnosis. 
 
a) Also to be investigated: inflammatory back pain, family history of psoriasis, SpA, 
inflammatory bowels diseases; check for inflammatory ocular conditions (iritis, uveitis). 
b) Located in the natal cleft, umbilicus, auricular ducts. 
PDUS = power-Doppler ultrasound scan; BMO = bone marrow oedema; MRI = magnetic 
resonance imaging; NSAIDs = non-steroidal anti-inflammatory drugs; Switch = intra-class 
change of biologic drug (e. g.: from one tumor necrosis factor α inhibitor to another); Swap = 
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inter-class change of biologic drug (e. g.: from tumor necrosis factor α inhibition to 
interleukin 17 axis targeting); PsA = psoriatic arthritis; FMS = fibromyalgia syndrome. 
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Features related to enthesitic psoriatic arthritis (PsA, on the left) and fibromyalgia syndrome 
(FMS, on the right). The two conditions could dynamically fade into each other over time. 
Inflammatory markers, like C-reactive protein, may be normal. Sensitive imaging 
investigations may yield uncertainties. 
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Figure 4 Clinical case: imaging supporting the clinician. Positron emission tomography 




A) 18-F-Na PET of a 55 years old female affected by FMS complaining pain at elbows, 
shoulders, cervical and low back pain for more than a year. No site of uptake were observed. 
B) 18-F-Na PET of a 51 years old woman, mild psoriasis, affected by widespread musculo-
skeletal pain. Initial diagnosis of fibromyalgia, amitriptyline and paracetamol were not 
effective. The investigation showed an increased uptake at sacro-iliac joints, sterno-clavicular 
joints, and trochanteric entheses (arrows). The following treatment with indomethacin and 
sulphasalazine led to significant improvement of symptoms. 
 
